Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Daewoong Pharmaceutical Co. LTD.
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A diagnosis of stable moderate to severe COPD as defined by GOLD (the Global Initiative for Chronic Obstructive Lung Disease) guidelines(http://www.goldcopd.org); a postbronchodilator FEV1/forced vital capacity \[FVC\] ratio \< 70% and FEV1 ≥ 30% to \<80% of the predicted value.
Current or former cigarette smokers with a smoking history of at least 10 pack-years.
You may not be if
History or current diagnosis of asthma
Patients who have been hospitalized for an acute COPD exacerbation within 3 months prior to Visit 1
Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks before Visit 1.
Patients with any clinically significant respiratory conditions other than COPD
Clareo Health | Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
